GL1X · GenesisL1 explorer

Research workbench

Crystal structure of M. tuberculosis C171Q kasa in complex with TLM3

Analyse Crystal structure of M. tuberculosis C171Q kasa in complex with TLM3 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4C6Z
Type
protein
Length
828 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
3-oxoacyl-[acyl-carrier-protein] synthase 1
EC
2.3.1.41
UniProt
I6Y8T4
Ligands
TLE, M7U, K
Pockets
8 · best druggability 0.79

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B3-oxoacyl-[acyl-carrier-protein] synthase 1 (EC 2.3.1.41)protein41439% helix, 21% strandI6Y8T4

Ligands and binding sites

  • TLE · (5R)-3-ethyl-4-hydroxy-5-methyl-5-[(1E)-2-methylbuta-1,3-dien-1-yl]thiophen-2(5H)-one · ligand · 2 copies · chains A, B
  • M7U · (2R)-2-(hexadecanoyloxy)-3-{[(10R)-10-methyloctadecanoyl]oxy}propyl phosphate · ligand · 2 copies · chains A, B
  • K · Potassium ion · metal · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 9 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14450.790.8744M7U, EDO
25010.780.8553M7U
32070.760.9039TLE
41890.740.9036TLE
5960.360.7419empty

Interfaces

1 interface between chains.

  • A–B · 3270 Ų buried · 42 hydrogen bonds · protein-protein

Compared structures

  • 4C6Z · Crystal structure of M. tuberculosis C171Q KasA in complex with TLM3 · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.